Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04515472 · ClinicalTrials.gov registry record · Early Phase 1
Effect of Gender Affirming Hormone Therapy on Glucose Metabolism
A Early Phase 1 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
NCT04515472: Clinical Trial Early Phase 1 study, sponsored by The University of Texas Health Science Center at San Antonio.
NCT04515472 is a Early Phase 1 study that was terminated before completion, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 24 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04515472, a Early Phase 1 study, was terminated before completion, sponsored by The University of Texas Health Science Center at San Antonio.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The study will test: 1. whether estrogen treatment in transwomen is associated with improved insulin sensitivity and beta cell function 2. whether testosterone treatment in transmen is associated with worsening insulin sensitivity and beta cell function 3. whether estrogen therapy leads to enhanced immune response in older transwormen
Primary Outcome
Change in GLP-1 in response to glucose
Interventions
- DRUG Botnia Clamp
- OTHER Withdrawal of Gender Affirming Hormone Therapy (GAHT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2020-06-17 |
| Est. Completion | 2025-03-17 |
| Phase | Early Phase 1 |
Why NCT04515472 stopped before completion
NCT04515472 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 2 interventions - of which Botnia Clamp is the first listed.
NCT04515472 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04515472 about?
NCT04515472 is a clinical study titled "Effect of Gender Affirming Hormone Therapy on Glucose Metabolism". The study will test: 1. whether estrogen treatment in transwomen is associated with improved insulin sensitivity and beta cell function 2. whether testosterone treatment in transmen is associated with worsening insulin sensitivity and beta cell function 3. whether estrogen therapy leads to enhanced...
What is the current status of trial NCT04515472?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2020-06-17. Estimated completion is 2025-03-17.
What interventions are being tested in trial NCT04515472?
The interventions under investigation include: Botnia Clamp (DRUG), Withdrawal of Gender Affirming Hormone Therapy (GAHT) (OTHER).
Who is sponsoring clinical trial NCT04515472?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04515472's enrollment target sits among peer trials
24 1037th of 2000 higher than 913 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI